血液悪性腫瘍を有する日本人患者を対象とした、治験薬（マプリルパセプト（PF-07901801））に関する調査研究

基本情報

NCT ID

NCT05567887

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

7

治験依頼者名

Pfizer

概要

The purpose of this clinical trial is to learn about how safe and tolerable is the study medicine (called maplirpacept (PF-07901801)) when taken for the treatment of lymphoma or multiple myeloma (a type of cancer that affects your body's infection-fighting cells, lymphocytes or plasma cell). This study is seeking participants who: * are 18 years of age or older * have worsening and difficult to manage type of lymphoma or multiple myeloma * Have adequately functioning organs * are not on long term use of steroids which are given either by mouth or as shots * have no major heart related disease etc. All participants in this study will receive maplirpacept (PF-07901801) as an IV infusion (given directly into a vein) at the study clinic every week. Participants will continue to receive maplirpacept (PF-07901801) until their progress of cancer worsens or the participants do not wish to take the study medicine. The experiences of the people receiving the study medicine will be collected. This will help to understand if the study medicine maplirpacept (PF-07901801), is safe and can be given to Japanese people.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)